KHK4083: Clinical Trials

2 trials of KHK4083, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1

Follow KHK4083: new trials by email Literature Review of KHK4083 trials Research Report on KHK4083

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Rocatinlimab, Placebo - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Phase 3CompletedAmgen2212023-06-072026-07-23
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Rocatinlimab, Placebo - Atopic Dermatitis
Phase 3TerminatedAmgen26212023-05-312026-07-16

Conditions studied

Dermatitis, Atopic (2)  ·  Eczema (1)

Sponsors

Amgen (2)

Countries

Canada (2)  ·  United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  China (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Finland (1)